The proportion of prostate cancer among PSA test-positives that is a positive predictive value (PPV) of the screening has been reported so far in two different ways, by dividing screen detected cancers by the number of biopsies (ERSPC trial) and by the number of PSA test-positives (PLCO trial) [16,17]. This evidence concerns the gene KLK3 and cancer.